Roderick S Tang
Overview
Explore the profile of Roderick S Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
599
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tioni M, Jordan R, Pena A, Garg A, Wu D, Phan S, et al.
NPJ Vaccines
. 2022 Jul;
7(1):85.
PMID: 35906244
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike...
2.
Lambert S, Aslam S, Stillman E, MacPhail M, Nelson C, Ro B, et al.
PLoS One
. 2015 Mar;
10(3):e0119509.
PMID: 25793508
Background: Illness associated with Respiratory Syncytial Virus (RSV) remains an unmet medical need in both full-term infants and older adults. The fusion glycoprotein (F) of RSV, which plays a key...
3.
Schickli J, Whitacre D, Tang R, Kaur J, Lawlor H, Peters C, et al.
J Clin Invest
. 2015 Mar;
125(4):1637-47.
PMID: 25751145
Respiratory syncytial virus (RSV) is the most common cause of serious viral bronchiolitis in infants, young children, and the elderly. Currently, there is not an FDA-approved vaccine available for RSV,...
4.
Malkin E, Yogev R, Abughali N, Sliman J, Wang C, Zuo F, et al.
PLoS One
. 2013 Nov;
8(10):e77104.
PMID: 24204744
Unlabelled: Despite substantial morbidity associated with respiratory syncytial virus (RSV) infection, there is no licensed vaccine. MEDI-559 is a live attenuated intranasal vaccine candidate being developed for prevention of lower...
5.
Lawlor H, Schickli J, Tang R
J Gen Virol
. 2013 Oct;
94(Pt 12):2627-2635.
PMID: 24092758
Respiratory syncytial virus (RSV) causes severe lower respiratory tract infection in children, especially in infants less than 1 year of age. There are currently no licensed vaccines against RSV. rA2ΔM2-2...
6.
Nelson C, Tang R, Stillman E
Vaccine
. 2013 Apr;
31(36):3756-62.
PMID: 23623857
MEDI-534 is the first live, attenuated and vectored respiratory syncytial virus (RSV) vaccine to be evaluated in seronegative children. It consists of a bovine/human parainfluenza virus type 3 (PIV3) backbone...
7.
Yang C, Wang C, Malkin E, Schickli J, Shambaugh C, Zuo F, et al.
Vaccine
. 2013 Apr;
31(26):2822-7.
PMID: 23602668
MEDI-534 is the first live vectored RSV vaccine candidate to be evaluated in seronegative children. It consists of the bovine parainfluenza virus type 3 (PIV3) genome with substituted human PIV3...
8.
Cherukuri A, Patton K, Gasser Jr R, Zuo F, Woo J, Esser M, et al.
Clin Vaccine Immunol
. 2012 Dec;
20(2):239-47.
PMID: 23239796
Respiratory syncytial virus (RSV) infects elderly (≥65 years) adults, causing medically attended illness and hospitalizations. While RSV neutralizing antibody levels correlate inversely with RSV-associated hospitalization in the elderly, the role...
9.
Schickli J, Kaur J, Tang R
Virus Res
. 2012 Jul;
169(1):38-47.
PMID: 22771939
MEDI-559 is a recombinant live attenuated intranasal RSV vaccine candidate currently being evaluated in 5 to <24 month old RSV seronegative infants for safety and immunogenicity. MEDI-559 and the previously...
10.
Schickli J, Dubovsky F, Tang R
Hum Vaccin
. 2009 Jun;
5(9):582-91.
PMID: 19556888
RSV bronchiolitis is the leading cause of infant hospitalization in industrialized countries. There is an unmet need to prevent RSV lower respiratory tract infection in young infants. Although many vaccinology...